Company intelligence / Profile preview

Alzinova

Mölndal, Sweden

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Alzinova is a clinical-stage Swedish biotech developing immunotherapies for Alzheimer’s disease. Its lead program, ALZ-101 (an active vaccine), has completed a Phase 1b study, while ALZ-201 (a monoclonal antibody) is in pre-clinical development. Both programs target amyloid-beta oligomers using the company's proprietary AβCC Peptide™ Technology.

Therapeutic areas: Neurology
Modalities: VaccineMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Alzinova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alzinova.

Explore the full profile